Brazil buys mpox vaccines for vulnerable groups
Brazil’s Ministry of Health orders up to 20,000 doses through the Pan American Health Organization.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
Brazil is buying up to 20,000 doses of mpox vaccine to replenish the national healthcare system’s strategic stock. Vaccination remains focused on groups at increased risk, while the number of recorded cases is far lower than during the 2022 outbreak.
Brazil’s Ministry of Health announced the purchase on 5 November. The doses are being acquired through the Pan American Health Organization’s (PAHO) Revolving Fund, with the aim of strengthening vaccine availability and the preparedness of the Sistema Único de Saúde (SUS).
According to the ministry, Brazil has recorded 665 confirmed mpox cases so far in 2026. That is 94 per cent fewer than in 2022, when the country reported more than 10,000 cases. The ministry presents the decline as part of the epidemiological context, but does not say that the purchase or vaccination caused it.
The national strategy prioritises people with HIV/AIDS whose CD4 count is below 100 per microlitre. According to the ministry, they face a greater risk of severe illness. The vaccination schedule consists of two doses 28 days apart. According to the ministry, remaining doses may also become available to people with HIV/AIDS with fewer than 200 CD4 cells, users of HIV pre-exposure prophylaxis and laboratory staff working with mpox samples.
The World Health Organization (WHO) supports a targeted approach and does not currently recommend mass vaccination of the entire population. According to the WHO, full vaccination with the MVA-BN vaccine reduces the risk of mpox by 82 per cent compared with unvaccinated people in available studies; after one dose, the reduction is 76 per cent. The WHO stresses that vaccinated people can still become infected and must continue taking precautions.
Alongside vaccination, the Brazilian authorities monitor suspected cases, conduct laboratory diagnostics and trace contacts of infected people. According to the ministry, the purchase is intended to strengthen vaccine availability and the healthcare system’s preparedness.
Also show the region and a close-up
One story, several perspectives
What is established
- Brazil is buying up to 20,000 doses of mpox vaccine.
- Vaccination is focused on people at increased risk of infection or severe illness.
- The WHO does not currently recommend mass vaccination of the entire population.
Left
Arguments A targeted strategy protects people facing the greatest health risks and prevents scarce vaccines from going mainly to lower-risk groups.
Values Equal access, public health and protection of vulnerable people.
Consequences The government must actively ensure that vulnerable groups are reached and that financial or social barriers do not prevent vaccination.
Centre
Arguments The combination of surveillance, a strategic stockpile and targeted vaccination is consistent with the available data and can be adjusted if the epidemiological picture changes.
Values Proportionality, evidence and efficient use of public funds.
Consequences The approach requires continuous monitoring and clear criteria for expanding or limiting the target group.
Right
Arguments A limited target group prevents unnecessary government spending and gives individuals and healthcare providers room to assess risks on a case-by-case basis.
Values Personal responsibility, restrained government intervention and efficiency.
Consequences The government must prevent precautionary policy from developing into broad measures without a clear epidemiological need.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The policy decision, figures and priority groups are documented in Brazilian government sources. The WHO confirms the targeted vaccination strategy and the stated effectiveness figures; the text makes no causal claim about the decline in the number of cases.
- confirmed Brazil is buying up to 20,000 doses of mpox vaccine through PAHO’s Revolving Fund. — Mentioned in the Brazilian ministry’s statement of 5 November 2026. source
- confirmed Brazil recorded 665 confirmed mpox cases in 2026, 94 per cent fewer than in 2022. — The figures appear in the Brazilian ministry’s statement. source
- confirmed Brazil’s strategy prioritises people with HIV/AIDS and fewer than 100 CD4 cells. — The prioritisation and the schedule of two doses 28 days apart are set out in the government information. source
- confirmed The WHO does not currently recommend mass vaccination and cites an 82 per cent lower risk after two doses of MVA-BN and 76 per cent after one dose. — The WHO page describes both the targeted approach and the effectiveness figures. source
Editor's note
The purchase and prioritisation are based on Brazilian government sources. The effectiveness figures come from the WHO; the decline in the number of Brazilian cases is not evidence that vaccination alone is responsible.Sources
- Ministério da Saúde autoriza aquisição de 20 mil doses da vacina contra mpox por meio da Opas — Ministério da Saúde do Brasil
- Nota Técnica Conjunta nº 403/2026-DPNI/SVSA-MS — Ministério da Saúde do Brasil
- Public advice on mpox vaccination — World Health Organization
More on this in Dutch media
- AD — „mpox vaccinatie”
- de Volkskrant — „mpox vaccinatie”
- RTL Nieuws — „mpox vaccinatie”